Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Multiple Myeloma Patients Treated with Direct Oral Anticoagulants for Immunomodulatory Drug Associated Venous Thromboembolism

Zachary Crowther, Jamie Doyle, Stanford Taylor, Nadia Ali, MD

Blood (2019) 134 (Supplement_1): 4964.

https://doi.org/10.1182/blood-2019-131396

Published: 2019

Journal Articles

Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus

Elena Monzón Manzano, Ihosvany Fernandez-Bello, Raul Justo Sanz, Larissa Valor, Francisco Javier López-Longo, Angel Robles, Teresa Álvarez Roman, Miguel A Canales, MD PhD, Victor Jimenez-Yuste, Nora Butta, PhD

Blood (2019) 134 (Supplement_1): 1141.

https://doi.org/10.1182/blood-2019-127991

Published: 2019

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

Reem Karmali, MD, Jeremy S. Abramson, MD MMSc, Deborah M. Stephens, DO, Jeffrey A. Barnes, MD PhD, Jason Kaplan, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Juehua Gao, MD PhD, Adam M. Petrich, MD, Ephraim Hochberg, MD, Ronald W. Takvorian, MD, Frank Kuhr, PhD, Valerie Nelson, MD MBA, Leo I. Gordon, MD, Barbara Pro, MD

Blood (2019) 134 (Supplement_1): 3990.

https://doi.org/10.1182/blood-2019-126920

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Victoria R. Alegria, Salman Ahmed, MD, Betsy Laplant, MS, Alak Manna, PhD, Ricardo Parrondo, MD, Vivek Roy, MD, Taimur Sher, MD, Brett Edwards, Stephanie Lanier, Keisha Jackson, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2019) 134 (Supplement_1): 3137.

https://doi.org/10.1182/blood-2019-128610

Published: 2019

Journal Articles

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Clare C. Sun, MD, Pia Nierman, RN, Inhye E. Ahn, MD, Janet Valdez, Jennifer Lotter, Susan Soto, Sarah E. M. Herman, PhD, Todd Covey, PhD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Dongmei Liu, PhD, Priti Patel, MD, Adrian Wiestner, MD

Blood (2018) 132 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2018-99-110395

Published: 2018

Journal Articles

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Meirav Kedmi, MD, Elena Ribakovsy, MD, Ohad Benjamini, MD, Ginette Schiby, MD, Iris Barshack, MD, Stephen P Raskin, MD, Yael Eshet, MD, Ramit Mehr, PhD, Guy Bitansky, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2018) 132 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2018-99-111658

Published: 2018

Journal Articles

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Lorraine Cafuir, MD, En Cheng, Christine L Kempton, MD MSc

Blood (2018) 132 (Supplement 1): 826.

https://doi.org/10.1182/blood-2018-99-110685

Published: 2018

Journal Articles

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, Heather A. Rasmussen, BS, Pamela S. Becker, MD, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2018-99-115476

Published: 2018

Journal Articles

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Xiaolan Shi, Lingzhi Yan, Jingjing Shang, Su Qu, Liqing Kang, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Shuang Yan, Yong Liu, Guanghua Chen, Ziling Zhu, Huirong Chang, Depei Wu, MDPhD, Lei Yu, ChengCheng Fu

Blood (2018) 132 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2018-99-117964

Published: 2018

Journal Articles

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for Chemosensitive Relapses in Patients with Follicular Lymphoma: A Prospective Multicenter Phase II Study from Lymphoma Study Association (LYSA) Centers

Herv Ghesquieres, Cecile Dalban, MSc, Emmanuelle Nicolas-Virelizier, MD, Fabrice Jardin, MD PhD, Fabien Le Bras, Steven Le Gouill, MD PhD, Rene-Olivier Casasnovas, MD, Seraphine Vizoso, PhD, Caroline Hernandez, MSc, Severine Metzger, MSc, David Perol, MD, Guillaume Cartron

Blood (2018) 132 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2018-99-116301

Published: 2018

Journal Articles

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Megan Sturdy, MD, Rebecca Ye, BA, Trevor L Jenkins, MD, James Driscoll, MD PhD, Paolo Caimi, MD, Leland Metheny, MD, Rachel Zebrowski, RN, Nicole Ferrari, Merle Kolk, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2018) 132 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2018-99-113828

Published: 2018

Journal Articles

A Prospective, Non-Randomized, Multicenter, Phase II Study to Assess Safety and Efficacy of the Infusion of Peripheral Blood Stem Cells Obtained from HLA-Haploidentical Familial Donors (mHaploSCI) after Standard Chemotherapy in Elderly Patients with Acute Myeloid Leukemia at Intermediate or Adverse Risk

Mirko Farina, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Arnalda Lanfranchi, Alessandra Beghin, Enrico Morello, MD, Marta Petullà, Erika Borlenghi, Chiara Cattaneo, MD, Roberto Cairoli, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 4464.

https://doi.org/10.1182/blood.V130.Suppl_1.4464.4464

Published: 2017

Journal Articles

Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

Blood (2017) 130 (Supplement 1): 497.

https://doi.org/10.1182/blood.V130.Suppl_1.497.497

Published: 2017

Journal Articles

The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study

Philip A Thompson, MBBS, Vincent Levy, MD PhD, Constantine S. Tam, MBBS, Chadi al Nawakil, MD, Francois Xavier Goudot, MD, Anne Quinquenel, MD, Loic Ysebaert, MD PhD, Anne-Sophie Michallet, MD, Marie Sarah Dilhuydy, MD, Eric W Van Den Neste, MD PhD, Jehan Dupuis, MD, Michael Keating, MBBS, Christophe Meune, MD PhD, Florence Cymbalista, MD PhD

Blood (2016) 128 (22): 3242.

https://doi.org/10.1182/blood.V128.22.3242.3242

Published: 2016

Journal Articles

Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study

Jong-Wook Lee, MD, Eric Scott Bachman, MD PhD, Rasha Aguzzi, MS, Jun Ho Jang, MD PhD, Jin Seok Kim, MD PhD, Scott T. Rottinghaus, MD, Lori Shafner, PhD, Jeff Szer, MB, BS, FRACP

Blood (2016) 128 (22): 2428.

https://doi.org/10.1182/blood.V128.22.2428.2428

Published: 2016

Journal Articles

Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: A Pooled-Analysis of Four Randomized Trials

Seongseok Yun, MD PhD, Nicole D. Vincelette, PhD, Utkarsh Acharya, DO, Ivo Abraham, PhD

Blood (2016) 128 (22): 5584.

https://doi.org/10.1182/blood.V128.22.5584.5584

Published: 2016

Journal Articles

Continued Use of Tinzaparin at Therapeutic Doses for Prophylaxis of Venous Thromboembolism in Patients with Intolerance to Antivitamins K

Maria Almudena Garcia Ruiz, DOCTOR AND HEMATOLOGY SPECIALIST, Francisco Jose Romero Martinez, DOCTOR, Estefania Morente Constantin, RESIDENT, Margarita Gomez Morales, DOCTOR AND HEMATOLOGIST, Manuel Jurado, MD

Blood (2015) 126 (23): 4735.

https://doi.org/10.1182/blood.V126.23.4735.4735

Published: 2015

Journal Articles

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Chaitra S. Ujjani, MD, Sin-Ho Jung, PhD, Brandelyn Pitcher, MS, Peter Martin, MD, Steven I. Park, MD, Kristie A. Blum, MD, Sonali M. Smith, MD, Myron S. Czuczman, MD, Matthew S. Davids, MD, John P. Leonard, MD, Bruce D. Cheson, MD

Blood (2015) 126 (23): 471.

https://doi.org/10.1182/blood.V126.23.471.471

Published: 2015

NARROW

Clinical Outcomes of Multiple Myeloma Patients Treated with Direct Oral Anticoagulants for Immunomodulatory Drug Associated Venous Thromboembolism

Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Outcomes of Direct Oral Anticoagulant- and Warfarin-Associated Hemorrhage: A Single Center Retrospective Cohort Study

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for Chemosensitive Relapses in Patients with Follicular Lymphoma: A Prospective Multicenter Phase II Study from Lymphoma Study Association (LYSA) Centers

Factors Influencing Incidence of Supraventricular Arrhythmias during and after Autologous Stem Cell Transplant in Multiple Myeloma

Phase II, Multicenter Trial, Exploring "Chemo-Sparing" Strategy Associating Obinutuzumab+Ibrutinib Followed By a MRD Driven Strategy, in Previously Untreated Symptomatic Medically Fit Chronic Lymphocytic Leukemia Patients (CLL): Preliminary Results of the Induction Phase of the Icll-07 Filo Study

The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study

Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study

Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: A Pooled-Analysis of Four Randomized Trials

Continued Use of Tinzaparin at Therapeutic Doses for Prophylaxis of Venous Thromboembolism in Patients with Intolerance to Antivitamins K

Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only